Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LivaNovaLIVN +0.58%78 EV-to-EBIT is 27.89 as of Aug. 09, 2026. GuruFocus rates LIVN with a GF Score™ of 78/100 and a GF Value™ of $63.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 472 Medical Devices & Instruments companies, LivaNova ranks worse than 69.28% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
LivaNova's Enterprise Value for the quarter that ended in Jun. 2026 was $4,462 Mil.
LivaNova's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova EV-to-EBIT Related Terms
LivaNova EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for LivaNova's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LivaNova's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where LivaNova's EV-to-EBIT falls into.
LivaNova's current Enterprise Value is $4,035 Mil.
LivaNova's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova (LIVN) has a EV-to-EBIT of 27.89 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LivaNova and its competitors. According to the industry distribution chart, LivaNova ranks #327 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 69.3%.
Is LivaNova's EV-to-EBIT too high?
LivaNova's current EV-to-EBIT is 27.89. The Medical Devices & Instruments industry median EV-to-EBIT is 19.02. LivaNova's value of 27.89 is 46.6% above this industry median. Based on the distribution chart, LivaNova ranks #327 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LivaNova has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's EV-to-EBIT compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #327 out of 472 companies for EV-to-EBIT. This places LivaNova in the lower half of its industry. The industry median EV-to-EBIT is 19.02. LivaNova's value of 27.89 is 46.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.02, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LivaNova's current EV-to-EBIT of 27.89 is 46.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LivaNova and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LivaNova's current EV-to-EBIT is 27.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Modestly Overvalued. The stock's GF Value™ is $63.02, compared to a current price of $76.23 — trading 21% above its estimated fair value. The current EV-to-EBIT is 27.89 and 46.6% above the Medical Devices & Instruments industry median of 19.02. LivaNova's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For LivaNova (LIVN), the current EV-to-EBIT is 27.89 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LivaNova (LIVN) Overvalued in 2026?
Based on GuruFocus' analysis, LivaNova stock appears to be overvalued.
The current stock price of $76.23 is trading 21% above its estimated GF Value™ of $63.02.
GuruFocus considers LivaNova to be Modestly Overvalued.
Key valuation signals for LIVN:
EV-to-EBIT: 27.89
GF Value™: $63.02 vs. price of $76.23 (21% above fair value)
Industry Position: 46.6% above the Medical Devices & Instruments median (#327 of 472)
No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
78GF Score
Get the complete analysis for LIVN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIVN has been successfully added to your 
